Back to Results

An Open-Label Study to Evaluate the Efficacy and Safety of Avatrombopag for the Treatment of Subjects with Thrombocytopenia Scheduled for a Surgical Procedure

Study category: Bones, Muscles, and Joints

Is this Study for You?

Let's Get Started!

Description

The purpose of this study is to test the safety and effectiveness of the study drug, avatrombopag, in subjects with thrombocytopenia undergoing an operation. Patients will receive either 60mg or 80mg of avatrombopag once daily by mouth for 5 days prior to surgery

Details
Age

Adult

Eligibility

Adult, undergoing surgery to critical site (i.e. spine), low platelet count prior to surgery

Detailed Eligibility: Can not have: history of blood clots, be on anticoagulant or antiplatelet therapy prior to surgery, alcohol dependence, active infection, significant cardiovascular disease, current malignancy, hepatic encephalopathy or hepatocellular carcinoma.

Phase

III - Research Studies that gather more information about a drug's safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs. These studies typically involve more participants.

Type of Study

Treatment

Location

University of Colorado Hospital

Principal Investigator
Peter Witt

Peter Witt

Study ID

Protocol Number: 18-0546

More information available at ClinicalTrials.gov: NCT03326843

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers